ID   TPP1_HUMAN              Reviewed;         563 AA.
AC   O14773; Q53HT1; Q5JAK6; Q6UX56; Q71JP6; Q96C37;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2006, sequence version 2.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=Tripeptidyl-peptidase 1;
DE            Short=TPP-1;
DE            EC=3.4.14.9;
DE   AltName: Full=Cell growth-inhibiting gene 1 protein;
DE   AltName: Full=Lysosomal pepstatin-insensitive protease;
DE            Short=LPIC;
DE   AltName: Full=Tripeptidyl aminopeptidase;
DE   AltName: Full=Tripeptidyl-peptidase I;
DE            Short=TPP-I;
DE   Flags: Precursor;
GN   Name=TPP1; Synonyms=CLN2; ORFNames=GIG1, UNQ267/PRO304;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE,
RP   VARIANTS CLN2 ARG-365 AND TYR-365, AND VARIANT HIS-175.
RC   TISSUE=Placenta;
RX   PubMed=9295267; DOI=10.1126/science.277.5333.1802;
RA   Sleat D.E., Donnelly R.J., Lackland H., Liu C.-G., Sohar I.,
RA   Pullarkat R.K., Lobel P.;
RT   "Association of mutations in a lysosomal protein with classical late-
RT   infantile neuronal ceroid lipofuscinosis.";
RL   Science 277:1802-1805(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=9653647; DOI=10.1006/geno.1998.5328;
RA   Liu C.-G., Sleat D.E., Donnelly R.J., Lobel P.;
RT   "Structural organization and sequence of CLN2, the defective gene in
RT   classical late infantile neuronal ceroid lipofuscinosis.";
RL   Genomics 50:206-212(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain cortex;
RA   Junaid M.A., Barua M., Pullarkat R.K.;
RT   "Bovine brain homolog of the tripeptidyl peptidase I which is
RT   deficient in the human classic late-infantile neuronal ceroid
RT   lipofuscinosis.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Kim J.W.;
RT   "Identification of a human growth inhibition gene 1 (GIG1).";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Adipose tissue;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 20-24; 196-200 AND 466-492, MUTAGENESIS, AND
RP   CHARACTERIZATION.
RX   PubMed=11054422; DOI=10.1074/jbc.M008562200;
RA   Lin L., Sohar I., Lackland H., Lobel P.;
RT   "The human CLN2 protein/tripeptidyl-peptidase I is a serine protease
RT   that autoactivates at acidic pH.";
RL   J. Biol. Chem. 276:2249-2255(2001).
RN   [9]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=12643545; DOI=10.1021/pr025562r;
RA   Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K.,
RA   Valencia J., Muller J., Vieira W.D., Watabe H., Shabanowitz J.,
RA   Hearing V.J., Hunt D.F., Appella E.;
RT   "Proteomic analysis of early melanosomes: identification of novel
RT   melanosomal proteins.";
RL   J. Proteome Res. 2:69-79(2003).
RN   [10]
RP   GLYCOSYLATION AT ASN-443.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [11]
RP   REVIEW ON VARIANTS.
RX   PubMed=10477428;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:3<199::AID-HUMU3>3.0.CO;2-A;
RA   Mole S.E., Mitchison H.M., Munroe P.B.;
RT   "Molecular basis of the neuronal ceroid lipofuscinoses: mutations in
RT   CLN1, CLN2, CLN3, and CLN5.";
RL   Hum. Mutat. 14:199-215(1999).
RN   [12]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [13]
RP   INTERACTION WITH CLN5, AND SUBCELLULAR LOCATION.
RX   PubMed=19941651; DOI=10.1186/1471-2121-10-83;
RA   Lyly A., von Schantz C., Heine C., Schmiedt M.L., Sipilae T.,
RA   Jalanko A., Kyttaelae A.;
RT   "Novel interactions of CLN5 support molecular networking between
RT   neuronal ceroid lipofuscinosis proteins.";
RL   BMC Cell Biol. 10:83-83(2009).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-210; ASN-222; ASN-313 AND
RP   ASN-443.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   CLEAVAGE OF PROPEPTIDE [LARGE SCALE ANALYSIS] AFTER GLY-195, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS), ACTIVE SITE, CALCIUM-BINDING
RP   SITES, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-210; ASN-286; ASN-313
RP   AND ASN-443.
RX   PubMed=19038966; DOI=10.1074/jbc.M806947200;
RA   Pal A., Kraetzner R., Gruene T., Grapp M., Schreiber K., Gronborg M.,
RA   Urlaub H., Becker S., Asif A.R., Gartner J., Sheldrick G.M.,
RA   Steinfeld R.;
RT   "Structure of tripeptidyl-peptidase I provides insight into the
RT   molecular basis of late infantile neuronal ceroid lipofuscinosis.";
RL   J. Biol. Chem. 284:3976-3984(2009).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 20-563, ACTIVE SITE,
RP   DISULFIDE BONDS, CALCIUM-BINDING SITES, SUBUNIT, AUTOPROTEOLYTIC
RP   CLEAVAGE, AND GLYCOSYLATION AT ASN-210; ASN-286; ASN-313 AND ASN-443.
RX   PubMed=19038967; DOI=10.1074/jbc.M806943200;
RA   Guhaniyogi J., Sohar I., Das K., Stock A.M., Lobel P.;
RT   "Crystal structure and autoactivation pathway of the precursor form of
RT   human tripeptidyl-peptidase 1, the enzyme deficient in late infantile
RT   ceroid lipofuscinosis.";
RL   J. Biol. Chem. 284:3985-3997(2009).
RN   [20]
RP   VARIANTS CLN2 ARG-77; ASN-287; LYS-343; ARG-365; TYR-365; ASP-385;
RP   GLU-389; HIS-422; HIS-447; GLU-454 AND LEU-475, AND VARIANT ARG-100.
RX   PubMed=10330339; DOI=10.1086/302427;
RA   Sleat D.E., Gin R.M., Sohar I., Wisniewski K., Sklower-Brooks S.,
RA   Pullarkat R.K., Palmer D.N., Lerner T.J., Boustany R.-M.N., Uldall P.,
RA   Siakotos A.N., Donnelly R.J., Lobel P.;
RT   "Mutational analysis of the defective protease in classic late-
RT   infantile neuronal ceroid lipofuscinosis, a neurodegenerative
RT   lysosomal storage disorder.";
RL   Am. J. Hum. Genet. 64:1511-1523(1999).
RN   [21]
RP   VARIANT CLN2 CYS-206.
RX   PubMed=10665500;
RX   DOI=10.1002/1531-8249(200002)47:2<254::AID-ANA19>3.3.CO;2-Z;
RA   Berry-Kravis E., Sleat D.E., Sohar I., Meyer P., Donnelly R.,
RA   Lobel P.;
RT   "Prenatal testing for late infantile neuronal ceroid lipofuscinosis.";
RL   Ann. Neurol. 47:254-257(2000).
RN   [22]
RP   VARIANTS CLN2 GLN-127; VAL-284; ASN-428 AND ARG-473.
RX   PubMed=11339651; DOI=10.1097/00125817-200011000-00002;
RA   Zhong N., Moroziewicz D.N., Ju W., Jurkiewicz A., Johnston L.,
RA   Wisniewski K.E., Brown W.T.;
RT   "Heterogeneity of late-infantile neuronal ceroid lipofuscinosis.";
RL   Genet. Med. 2:312-318(2000).
RN   [23]
RP   VARIANT CLN2 ARG-473.
RX   PubMed=11241479;
RX   DOI=10.1002/1096-8628(2001)9999:9999<::AID-AJMG1145>3.0.CO;2-Z;
RA   Lam C.W., Poon P.M., Tong S.F., Ko C.H.;
RT   "Two novel CLN2 gene mutations in a Chinese patient with classical
RT   late-infantile neuronal ceroid lipofuscinosis.";
RL   Am. J. Med. Genet. 99:161-163(2001).
RN   [24]
RP   VARIANT CLN2 LEU-202.
RX   PubMed=11589012; DOI=10.1053/ejpn.2000.0427;
RA   Mole S.E., Zhong N.A., Sarpong A., Logan W.P., Hofmann S., Yi W.,
RA   Franken P.F., van Diggelen O.P., Breuning M.H., Moroziewicz D., Ju W.,
RA   Salonen T., Holmberg V., Jaervelae I., Taschner P.E.M.;
RT   "New mutations in the neuronal ceroid lipofuscinosis genes.";
RL   Eur. J. Paediatr. Neurol. 5:7-10(2001).
RN   [25]
RP   CHARACTERIZATION OF VARIANTS ARG-100; GLU-389 AND HIS-447.
RX   PubMed=11462245; DOI=10.1002/humu.1170;
RA   Lin L., Lobel P.;
RT   "Expression and analysis of CLN2 variants in CHO cells: Q100R
RT   represents a polymorphism, and G389E and R447H represent loss-of-
RT   function mutations.";
RL   Hum. Mutat. 18:165-165(2001).
RN   [26]
RP   VARIANTS CLN2 GLN-127; SER-286 AND PRO-353.
RX   PubMed=12376936; DOI=10.1002/ajmg.10660;
RA   Steinfeld R., Heim P., von Gregory H., Meyer K., Ullrich K.,
RA   Goebel H.H., Kohlschutter A.;
RT   "Late infantile neuronal ceroid lipofuscinosis: quantitative
RT   description of the clinical course in patients with CLN2 mutations.";
RL   Am. J. Med. Genet. 112:347-354(2002).
RN   [27]
RP   VARIANTS CLN2 MET-277; PRO-278; VAL-284 AND CYS-481.
RX   PubMed=12414822; DOI=10.1136/jmg.39.11.822;
RA   Ju W., Zhong R., Moore S., Moroziewicz D., Currie J.R., Parfrey P.,
RA   Brown W.T., Zhong N.;
RT   "Identification of novel CLN2 mutations shows Canadian specific NCL2
RT   alleles.";
RL   J. Med. Genet. 39:822-825(2002).
RN   [28]
RP   VARIANT CLN2 HIS-206.
RX   PubMed=12698559;
RA   Bukina A.M., Tsvetkova I.V., Semiachkina A.N., Il'ina E.S.;
RT   "Tripeptidyl peptidase 1 deficiency in neuronal ceroid lipofuscinosis.
RT   A novel mutation.";
RL   Vopr. Med. Khim. 48:594-598(2002).
RN   [29]
RP   CHARACTERIZATION OF VARIANT CLN2 SER-286.
RX   PubMed=14736728; DOI=10.1093/glycob/cwh054;
RA   Tsiakas K., Steinfeld R., Storch S., Ezaki J., Lukacs Z., Kominami E.,
RA   Kohlschuetter A., Ullrich K., Braulke T.;
RT   "Mutation of the glycosylated asparagine residue 286 in human CLN2
RT   protein results in loss of enzymatic activity.";
RL   Glycobiology 14:1C-5C(2004).
RN   [30]
RP   VARIANT CLN2 ARG-482.
RX   PubMed=19201763; DOI=10.1093/brain/awn366;
RA   Kousi M., Siintola E., Dvorakova L., Vlaskova H., Turnbull J.,
RA   Topcu M., Yuksel D., Gokben S., Minassian B.A., Elleder M., Mole S.E.,
RA   Lehesjoki A.-E.;
RT   "Mutations in CLN7/MFSD8 are a common cause of variant late-infantile
RT   neuronal ceroid lipofuscinosis.";
RL   Brain 132:810-819(2009).
RN   [31]
RP   VARIANT CLN2 SER-544, AND CHARACTERIZATION OF VARIANTS CLN2 ARG-77;
RP   GLN-127; LEU-202; CYS-206; MET-277; VAL-284; SER-286; ASN-287;
RP   LYS-343; ARG-365; HIS-422; HIS-447; LEU-475 AND SER-544.
RX   PubMed=20340139; DOI=10.1002/humu.21251;
RA   Walus M., Kida E., Golabek A.A.;
RT   "Functional consequences and rescue potential of pathogenic missense
RT   mutations in tripeptidyl peptidase I.";
RL   Hum. Mutat. 31:710-721(2010).
RN   [32]
RP   VARIANTS CLN2 ARG-278 AND HIS-422.
RX   PubMed=22612257; DOI=10.1111/j.1528-1167.2012.03516.x;
RA   Lemke J.R., Riesch E., Scheurenbrand T., Schubach M., Wilhelm C.,
RA   Steiner I., Hansen J., Courage C., Gallati S., Buerki S., Strozzi S.,
RA   Simonetti B.G., Grunt S., Steinlin M., Alber M., Wolff M.,
RA   Klopstock T., Prott E.C., Lorenz R., Spaich C., Rona S.,
RA   Lakshminarasimhan M., Kroell J., Dorn T., Kraemer G., Synofzik M.,
RA   Becker F., Weber Y.G., Lerche H., Boehm D., Biskup S.;
RT   "Targeted next generation sequencing as a diagnostic tool in epileptic
RT   disorders.";
RL   Epilepsia 53:1387-1398(2012).
RN   [33]
RP   VARIANTS CLN2 THR-62; HIS-209; GLN-266; GLN-339; ARG-382; VAL-448;
RP   CYS-501; TYR-504 AND ARG-548.
RX   PubMed=21990111; DOI=10.1002/humu.21624;
RA   Kousi M., Lehesjoki A.E., Mole S.E.;
RT   "Update of the mutation spectrum and clinical correlations of over 360
RT   mutations in eight genes that underlie the neuronal ceroid
RT   lipofuscinoses.";
RL   Hum. Mutat. 33:42-63(2012).
RN   [34]
RP   VARIANT SCAR7 GLY-466.
RX   PubMed=23418007; DOI=10.1002/humu.22292;
RA   Sun Y., Almomani R., Breedveld G.J., Santen G.W., Aten E.,
RA   Lefeber D.J., Hoff J.I., Brusse E., Verheijen F.W., Verdijk R.M.,
RA   Kriek M., Oostra B., Breuning M.H., Losekoot M., den Dunnen J.T.,
RA   van de Warrenburg B.P., Maat-Kievit A.J.;
RT   "Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by
RT   variants in TPP1, the gene involved in classic late-infantile neuronal
RT   ceroid lipofuscinosis 2 disease (CLN2 disease).";
RL   Hum. Mutat. 34:706-713(2013).
CC   -!- FUNCTION: Lysosomal serine protease with tripeptidyl-peptidase I
CC       activity. May act as a non-specific lysosomal peptidase which
CC       generates tripeptides from the breakdown products produced by
CC       lysosomal proteinases. Requires substrates with an unsubstituted
CC       N-terminus (By similarity). {ECO:0000250|UniProtKB:Q9EQV6}.
CC   -!- CATALYTIC ACTIVITY: Release of an N-terminal tripeptide from a
CC       polypeptide, but also has endopeptidase activity.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:19038966,
CC         ECO:0000269|PubMed:19038967};
CC       Note=Binds 1 Ca(2+) ion per subunit. {ECO:0000269|PubMed:19038966,
CC       ECO:0000269|PubMed:19038967};
CC   -!- SUBUNIT: Monomer (PubMed:19038967). Interacts with CLN5
CC       (PubMed:19941651). {ECO:0000269|PubMed:19038967,
CC       ECO:0000269|PubMed:19941651}.
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:19941651}.
CC       Melanosome {ECO:0000269|PubMed:12643545}. Note=Identified by mass
CC       spectrometry in melanosome fractions from stage I to stage IV.
CC       {ECO:0000269|PubMed:12643545}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O14773-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14773-2; Sequence=VSP_013118;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in all tissues examined with highest
CC       levels in heart and placenta and relatively similar levels in
CC       other tissues.
CC   -!- PTM: Activated by autocatalytic proteolytical processing upon
CC       acidification. N-glycosylation is required for processing and
CC       activity. {ECO:0000269|PubMed:12754519,
CC       ECO:0000269|PubMed:19038966, ECO:0000269|PubMed:19038967,
CC       ECO:0000269|PubMed:19159218}.
CC   -!- DISEASE: Ceroid lipofuscinosis, neuronal, 2 (CLN2) [MIM:204500]: A
CC       form of neuronal ceroid lipofuscinosis. Neuronal ceroid
CC       lipofuscinoses are progressive neurodegenerative, lysosomal
CC       storage diseases characterized by intracellular accumulation of
CC       autofluorescent liposomal material, and clinically by seizures,
CC       dementia, visual loss, and/or cerebral atrophy. The lipopigment
CC       pattern seen most often in CLN2 consists of curvilinear profiles.
CC       {ECO:0000269|PubMed:10330339, ECO:0000269|PubMed:10665500,
CC       ECO:0000269|PubMed:11241479, ECO:0000269|PubMed:11339651,
CC       ECO:0000269|PubMed:11589012, ECO:0000269|PubMed:12376936,
CC       ECO:0000269|PubMed:12414822, ECO:0000269|PubMed:12698559,
CC       ECO:0000269|PubMed:14736728, ECO:0000269|PubMed:19201763,
CC       ECO:0000269|PubMed:20340139, ECO:0000269|PubMed:21990111,
CC       ECO:0000269|PubMed:22612257, ECO:0000269|PubMed:9295267}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Spinocerebellar ataxia, autosomal recessive, 7 (SCAR7)
CC       [MIM:609270]: Spinocerebellar ataxia defines a clinically and
CC       genetically heterogeneous group of cerebellar disorders. Patients
CC       show progressive incoordination of gait and often poor
CC       coordination of hands, speech and eye movements, due to
CC       degeneration of the cerebellum with variable involvement of the
CC       brainstem and spinal cord. SCAR7 patients show difficulty walking
CC       and writing, dysarthria, limb ataxia, and cerebellar atrophy.
CC       {ECO:0000269|PubMed:23418007}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAM08412.1; Type=Miscellaneous discrepancy; Note=Incorrectly indicated as originating from bovine.; Evidence={ECO:0000305};
CC       Sequence=AAQ88866.1; Type=Frameshift; Positions=551; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NCL CLN2; Note=Neural Ceroid Lipofuscinoses
CC       mutation db;
CC       URL="http://www.ucl.ac.uk/ncl/cln2.shtml";
CC   -!- WEB RESOURCE: Name=Mendelian genes trieptidyl peptidase I (TPP1);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/TPP1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF017456; AAB80725.1; -; mRNA.
DR   EMBL; AF039704; AAC98480.1; -; Genomic_DNA.
DR   EMBL; AF491290; AAM08412.1; ALT_SEQ; mRNA.
DR   EMBL; AY268890; AAQ72732.1; -; mRNA.
DR   EMBL; AY358502; AAQ88866.1; ALT_FRAME; mRNA.
DR   EMBL; AK222499; BAD96219.1; -; mRNA.
DR   EMBL; BC014863; AAH14863.1; -; mRNA.
DR   CCDS; CCDS7770.1; -. [O14773-1]
DR   RefSeq; NP_000382.3; NM_000391.3. [O14773-1]
DR   UniGene; Hs.523454; -.
DR   PDB; 1R60; Model; -; A=196-563.
DR   PDB; 3EDY; X-ray; 1.85 A; A=20-563.
DR   PDB; 3EE6; X-ray; 2.35 A; A/B=1-563.
DR   PDBsum; 1R60; -.
DR   PDBsum; 3EDY; -.
DR   PDBsum; 3EE6; -.
DR   ProteinModelPortal; O14773; -.
DR   SMR; O14773; -.
DR   BioGrid; 107611; 20.
DR   DIP; DIP-47434N; -.
DR   IntAct; O14773; 24.
DR   MINT; MINT-5002180; -.
DR   STRING; 9606.ENSP00000299427; -.
DR   MEROPS; S53.003; -.
DR   iPTMnet; O14773; -.
DR   PhosphoSitePlus; O14773; -.
DR   BioMuta; TPP1; -.
DR   EPD; O14773; -.
DR   MaxQB; O14773; -.
DR   PaxDb; O14773; -.
DR   PeptideAtlas; O14773; -.
DR   PRIDE; O14773; -.
DR   DNASU; 1200; -.
DR   Ensembl; ENST00000299427; ENSP00000299427; ENSG00000166340. [O14773-1]
DR   Ensembl; ENST00000533371; ENSP00000437066; ENSG00000166340. [O14773-2]
DR   GeneID; 1200; -.
DR   KEGG; hsa:1200; -.
DR   UCSC; uc001mek.2; human. [O14773-1]
DR   CTD; 1200; -.
DR   DisGeNET; 1200; -.
DR   GeneCards; TPP1; -.
DR   GeneReviews; TPP1; -.
DR   H-InvDB; HIX0009410; -.
DR   HGNC; HGNC:2073; TPP1.
DR   HPA; HPA037709; -.
DR   HPA; HPA044868; -.
DR   MalaCards; TPP1; -.
DR   MIM; 204500; phenotype.
DR   MIM; 607998; gene.
DR   MIM; 609270; phenotype.
DR   neXtProt; NX_O14773; -.
DR   OpenTargets; ENSG00000166340; -.
DR   Orphanet; 284324; Childhood-onset autosomal recessive slowly progressive spinocerebellar ataxia.
DR   Orphanet; 228349; CLN2 disease.
DR   PharmGKB; PA26600; -.
DR   eggNOG; ENOG410IICY; Eukaryota.
DR   eggNOG; COG4934; LUCA.
DR   GeneTree; ENSGT00390000008684; -.
DR   HOGENOM; HOG000171253; -.
DR   HOVERGEN; HBG004449; -.
DR   InParanoid; O14773; -.
DR   KO; K01279; -.
DR   OMA; GNFAHQA; -.
DR   OrthoDB; EOG091G059I; -.
DR   PhylomeDB; O14773; -.
DR   TreeFam; TF333497; -.
DR   BRENDA; 3.4.14.9; 2681.
DR   Reactome; R-HSA-381038; XBP1(S) activates chaperone genes.
DR   SABIO-RK; O14773; -.
DR   SignaLink; O14773; -.
DR   ChiTaRS; TPP1; human.
DR   EvolutionaryTrace; O14773; -.
DR   GeneWiki; Tripeptidyl_peptidase_I; -.
DR   GenomeRNAi; 1200; -.
DR   PMAP-CutDB; O14773; -.
DR   PRO; PR:O14773; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000166340; -.
DR   CleanEx; HS_TPP1; -.
DR   ExpressionAtlas; O14773; baseline and differential.
DR   Genevisible; O14773; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0004175; F:endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008233; F:peptidase activity; IMP:UniProtKB.
DR   GO; GO:0042277; F:peptide binding; ISS:UniProtKB.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0008236; F:serine-type peptidase activity; IMP:UniProtKB.
DR   GO; GO:0008240; F:tripeptidyl-peptidase activity; IDA:UniProtKB.
DR   GO; GO:0045453; P:bone resorption; IMP:UniProtKB.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0030855; P:epithelial cell differentiation; IEP:UniProtKB.
DR   GO; GO:0036498; P:IRE1-mediated unfolded protein response; TAS:Reactome.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0007040; P:lysosome organization; ISS:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IMP:UniProtKB.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; ISS:UniProtKB.
DR   GO; GO:0043171; P:peptide catabolic process; IMP:UniProtKB.
DR   GO; GO:0030163; P:protein catabolic process; NAS:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IMP:UniProtKB.
DR   CDD; cd04056; Peptidases_S53; 1.
DR   CDD; cd11377; Pro-peptidase_S53; 1.
DR   Gene3D; 3.40.50.200; -; 1.
DR   InterPro; IPR009020; Peptidase/Inhibitor_I9.
DR   InterPro; IPR000209; Peptidase_S8/S53_dom.
DR   InterPro; IPR015366; S53_propep.
DR   InterPro; IPR030400; Sedolisin_dom.
DR   Pfam; PF09286; Pro-kuma_activ; 1.
DR   SMART; SM00944; Pro-kuma_activ; 1.
DR   SUPFAM; SSF52743; SSF52743; 1.
DR   SUPFAM; SSF54897; SSF54897; 1.
DR   PROSITE; PS51695; SEDOLISIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autocatalytic cleavage; Calcium;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Epilepsy; Glycoprotein; Hydrolase; Lysosome;
KW   Metal-binding; Neurodegeneration; Neuronal ceroid lipofuscinosis;
KW   Polymorphism; Protease; Reference proteome; Serine protease; Signal;
KW   Spinocerebellar ataxia; Zymogen.
FT   SIGNAL        1     19       {ECO:0000269|PubMed:11054422}.
FT   PROPEP       20    195       Removed in mature form.
FT                                {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|PubMed:11054422}.
FT                                /FTId=PRO_0000027374.
FT   CHAIN       196    563       Tripeptidyl-peptidase 1.
FT                                /FTId=PRO_0000027375.
FT   DOMAIN      199    563       Peptidase S53.
FT   ACT_SITE    272    272       Charge relay system.
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   ACT_SITE    276    276       Charge relay system.
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   ACT_SITE    475    475       Charge relay system.
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   METAL       517    517       Calcium. {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   METAL       518    518       Calcium; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   METAL       539    539       Calcium; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   METAL       541    541       Calcium; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   METAL       543    543       Calcium. {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   CARBOHYD    210    210       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    222    222       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    286    286       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   CARBOHYD    313    313       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    443    443       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967,
FT                                ECO:0000269|PubMed:19159218}.
FT   DISULFID    111    122       {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   DISULFID    365    526       {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   DISULFID    522    537       {ECO:0000269|PubMed:19038966,
FT                                ECO:0000269|PubMed:19038967}.
FT   VAR_SEQ       1    243       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_013118.
FT   VARIANT      62     62       S -> L (in dbSNP:rs2734715).
FT                                /FTId=VAR_037572.
FT   VARIANT      62     62       S -> T (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066883.
FT   VARIANT      77     77       G -> R (in CLN2; displays very low
FT                                residual enzyme activity; altered
FT                                intracellular trafficking;
FT                                dbSNP:rs121908195).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_009603.
FT   VARIANT     100    100       Q -> R (in dbSNP:rs1800746).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:11462245}.
FT                                /FTId=VAR_009604.
FT   VARIANT     127    127       R -> Q (in CLN2; displays residual enzyme
FT                                activity; effectively transported to the
FT                                lysosome; dbSNP:rs121908204).
FT                                {ECO:0000269|PubMed:11339651,
FT                                ECO:0000269|PubMed:12376936,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_016790.
FT   VARIANT     153    153       S -> P (in CLN2).
FT                                /FTId=VAR_016791.
FT   VARIANT     175    175       R -> H (in dbSNP:rs764922748).
FT                                {ECO:0000269|PubMed:9295267}.
FT                                /FTId=VAR_005642.
FT   VARIANT     185    185       R -> C (in dbSNP:rs34758634).
FT                                /FTId=VAR_037573.
FT   VARIANT     202    202       P -> L (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs121908205).
FT                                {ECO:0000269|PubMed:11589012,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_063640.
FT   VARIANT     206    206       R -> C (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs28940573).
FT                                {ECO:0000269|PubMed:10665500,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_009605.
FT   VARIANT     206    206       R -> H (in CLN2; dbSNP:rs121908209).
FT                                {ECO:0000269|PubMed:12698559}.
FT                                /FTId=VAR_016792.
FT   VARIANT     209    209       Y -> H (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066884.
FT   VARIANT     266    266       R -> Q (in CLN2; dbSNP:rs757953998).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066885.
FT   VARIANT     277    277       V -> M (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; demonstrates enhanced
FT                                processing in response to folding
FT                                improvement treatment;
FT                                dbSNP:rs121908207).
FT                                {ECO:0000269|PubMed:12414822,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_016793.
FT   VARIANT     278    278       Q -> P (in CLN2).
FT                                {ECO:0000269|PubMed:12414822}.
FT                                /FTId=VAR_016794.
FT   VARIANT     278    278       Q -> R (in CLN2; dbSNP:rs796053439).
FT                                {ECO:0000269|PubMed:22612257}.
FT                                /FTId=VAR_072749.
FT   VARIANT     284    284       G -> V (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs119455957).
FT                                {ECO:0000269|PubMed:11339651,
FT                                ECO:0000269|PubMed:12414822,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_016795.
FT   VARIANT     286    286       N -> S (in CLN2; enzymatically inactive;
FT                                lacks one oligosaccharide chain resulting
FT                                in enzymatic inactivation and possibly
FT                                prelysosomal protein degradation; altered
FT                                intracellular trafficking;
FT                                dbSNP:rs119455958).
FT                                {ECO:0000269|PubMed:12376936,
FT                                ECO:0000269|PubMed:14736728,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_016796.
FT   VARIANT     287    287       I -> N (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs121908196).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_009606.
FT   VARIANT     339    339       R -> Q (in CLN2; dbSNP:rs765380155).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066886.
FT   VARIANT     343    343       E -> K (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs121908197).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_009607.
FT   VARIANT     353    353       T -> P (in CLN2; dbSNP:rs121908206).
FT                                {ECO:0000269|PubMed:12376936}.
FT                                /FTId=VAR_016797.
FT   VARIANT     365    365       C -> R (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking; dbSNP:rs119455953).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139,
FT                                ECO:0000269|PubMed:9295267}.
FT                                /FTId=VAR_005643.
FT   VARIANT     365    365       C -> Y (in CLN2; dbSNP:rs119455954).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:9295267}.
FT                                /FTId=VAR_005644.
FT   VARIANT     382    382       S -> R (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066887.
FT   VARIANT     385    385       V -> D (in CLN2; dbSNP:rs121908198).
FT                                {ECO:0000269|PubMed:10330339}.
FT                                /FTId=VAR_009608.
FT   VARIANT     389    389       G -> E (in CLN2; dbSNP:rs121908199).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:11462245}.
FT                                /FTId=VAR_009609.
FT   VARIANT     422    422       Q -> H (in CLN2; displays no residual
FT                                enzyme activity; altered intracellular
FT                                trafficking;; dbSNP:rs121908200).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139,
FT                                ECO:0000269|PubMed:22612257}.
FT                                /FTId=VAR_009610.
FT   VARIANT     428    428       K -> N (in CLN2).
FT                                {ECO:0000269|PubMed:11339651}.
FT                                /FTId=VAR_016798.
FT   VARIANT     447    447       R -> H (in CLN2; displays very low
FT                                residual enzyme activity; altered
FT                                intracellular trafficking; demonstrates
FT                                enhanced processing in response to
FT                                folding improvement treatment; shows a
FT                                five fold increase under permissive
FT                                temperature conditions;
FT                                dbSNP:rs119455956).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:11462245,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_005645.
FT   VARIANT     448    448       A -> V (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066888.
FT   VARIANT     454    454       A -> E (in CLN2; dbSNP:rs121908201).
FT                                {ECO:0000269|PubMed:10330339}.
FT                                /FTId=VAR_009611.
FT   VARIANT     466    466       V -> G (in SCAR7; dbSNP:rs398122959).
FT                                {ECO:0000269|PubMed:23418007}.
FT                                /FTId=VAR_070917.
FT   VARIANT     473    473       G -> R (in CLN2; dbSNP:rs121908203).
FT                                {ECO:0000269|PubMed:11241479,
FT                                ECO:0000269|PubMed:11339651}.
FT                                /FTId=VAR_016799.
FT   VARIANT     475    475       S -> L (in CLN2; displays no residual
FT                                enzyme activity; effectively transported
FT                                to the lysosome; dbSNP:rs121908202).
FT                                {ECO:0000269|PubMed:10330339,
FT                                ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_009612.
FT   VARIANT     481    481       F -> C (in CLN2).
FT                                {ECO:0000269|PubMed:12414822}.
FT                                /FTId=VAR_016800.
FT   VARIANT     482    482       G -> R (in CLN2; dbSNP:rs121908208).
FT                                {ECO:0000269|PubMed:19201763}.
FT                                /FTId=VAR_058435.
FT   VARIANT     501    501       G -> C (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066889.
FT   VARIANT     504    504       N -> Y (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066890.
FT   VARIANT     544    544       P -> S (in CLN2; displays residual enzyme
FT                                activity; effectively transported to the
FT                                lysosome; dbSNP:rs121908210).
FT                                {ECO:0000269|PubMed:20340139}.
FT                                /FTId=VAR_063641.
FT   VARIANT     548    548       W -> R (in CLN2).
FT                                {ECO:0000269|PubMed:21990111}.
FT                                /FTId=VAR_066891.
FT   MUTAGEN     236    236       H->A: No effect.
FT                                {ECO:0000269|PubMed:11054422}.
FT   MUTAGEN     360    360       D->A: Inactive. Impaired processing.
FT                                {ECO:0000269|PubMed:11054422}.
FT   MUTAGEN     475    475       S->A: Inactive. Impaired processing.
FT                                {ECO:0000269|PubMed:11054422}.
FT   MUTAGEN     517    517       D->A: Inactive. Impaired processing.
FT                                {ECO:0000269|PubMed:11054422}.
FT   CONFLICT    115    115       I -> N (in Ref. 6; BAD96219).
FT                                {ECO:0000305}.
FT   CONFLICT    373    373       Q -> E (in Ref. 7; AAH14863).
FT                                {ECO:0000305}.
FT   STRAND       35     40       {ECO:0000244|PDB:3EDY}.
FT   STRAND       46     53       {ECO:0000244|PDB:3EDY}.
FT   HELIX        58     69       {ECO:0000244|PDB:3EDY}.
FT   TURN         74     77       {ECO:0000244|PDB:3EDY}.
FT   HELIX        82     89       {ECO:0000244|PDB:3EDY}.
FT   HELIX        93    106       {ECO:0000244|PDB:3EDY}.
FT   STRAND      109    113       {ECO:0000244|PDB:3EDY}.
FT   STRAND      119    125       {ECO:0000244|PDB:3EDY}.
FT   HELIX       126    132       {ECO:0000244|PDB:3EDY}.
FT   STRAND      139    143       {ECO:0000244|PDB:3EDY}.
FT   TURN        144    147       {ECO:0000244|PDB:3EDY}.
FT   STRAND      148    152       {ECO:0000244|PDB:3EDY}.
FT   HELIX       161    163       {ECO:0000244|PDB:3EDY}.
FT   TURN        164    166       {ECO:0000244|PDB:3EDY}.
FT   STRAND      167    170       {ECO:0000244|PDB:3EDY}.
FT   HELIX       202    208       {ECO:0000244|PDB:3EDY}.
FT   STRAND      219    221       {ECO:0000244|PDB:3EDY}.
FT   STRAND      224    229       {ECO:0000244|PDB:3EDY}.
FT   HELIX       237    247       {ECO:0000244|PDB:3EDY}.
FT   STRAND      258    262       {ECO:0000244|PDB:3EDY}.
FT   HELIX       271    283       {ECO:0000244|PDB:3EDY}.
FT   TURN        284    286       {ECO:0000244|PDB:3EE6}.
FT   STRAND      287    292       {ECO:0000244|PDB:3EDY}.
FT   TURN        295    300       {ECO:0000244|PDB:3EE6}.
FT   HELIX       303    311       {ECO:0000244|PDB:3EDY}.
FT   STRAND      319    324       {ECO:0000244|PDB:3EDY}.
FT   HELIX       329    331       {ECO:0000244|PDB:3EDY}.
FT   HELIX       334    349       {ECO:0000244|PDB:3EDY}.
FT   STRAND      353    357       {ECO:0000244|PDB:3EDY}.
FT   STRAND      366    368       {ECO:0000244|PDB:3EDY}.
FT   STRAND      371    373       {ECO:0000244|PDB:3EDY}.
FT   TURN        379    381       {ECO:0000244|PDB:3EDY}.
FT   STRAND      385    397       {ECO:0000244|PDB:3EDY}.
FT   STRAND      402    404       {ECO:0000244|PDB:3EDY}.
FT   STRAND      411    417       {ECO:0000244|PDB:3EDY}.
FT   HELIX       420    422       {ECO:0000244|PDB:3EDY}.
FT   HELIX       423    432       {ECO:0000244|PDB:3EDY}.
FT   HELIX       439    441       {ECO:0000244|PDB:3EDY}.
FT   STRAND      446    449       {ECO:0000244|PDB:3EDY}.
FT   STRAND      451    455       {ECO:0000244|PDB:3EDY}.
FT   STRAND      457    463       {ECO:0000244|PDB:3EDY}.
FT   STRAND      466    471       {ECO:0000244|PDB:3EDY}.
FT   HELIX       474    494       {ECO:0000244|PDB:3EDY}.
FT   HELIX       504    509       {ECO:0000244|PDB:3EDY}.
FT   TURN        510    514       {ECO:0000244|PDB:3EDY}.
FT   STRAND      522    525       {ECO:0000244|PDB:3EDY}.
FT   TURN        529    533       {ECO:0000244|PDB:3EDY}.
FT   STRAND      534    537       {ECO:0000244|PDB:3EDY}.
FT   TURN        544    546       {ECO:0000244|PDB:3EDY}.
FT   HELIX       553    558       {ECO:0000244|PDB:3EDY}.
SQ   SEQUENCE   563 AA;  61248 MW;  7299D902F6AE8555 CRC64;
     MGLQACLLGL FALILSGKCS YSPEPDQRRT LPPGWVSLGR ADPEEELSLT FALRQQNVER
     LSELVQAVSD PSSPQYGKYL TLENVADLVR PSPLTLHTVQ KWLLAAGAQK CHSVITQDFL
     TCWLSIRQAE LLLPGAEFHH YVGGPTETHV VRSPHPYQLP QALAPHVDFV GGLHRFPPTS
     SLRQRPEPQV TGTVGLHLGV TPSVIRKRYN LTSQDVGSGT SNNSQACAQF LEQYFHDSDL
     AQFMRLFGGN FAHQASVARV VGQQGRGRAG IEASLDVQYL MSAGANISTW VYSSPGRHEG
     QEPFLQWLML LSNESALPHV HTVSYGDDED SLSSAYIQRV NTELMKAAAR GLTLLFASGD
     SGAGCWSVSG RHQFRPTFPA SSPYVTTVGG TSFQEPFLIT NEIVDYISGG GFSNVFPRPS
     YQEEAVTKFL SSSPHLPPSS YFNASGRAYP DVAALSDGYW VVSNRVPIPW VSGTSASTPV
     FGGILSLINE HRILSGRPPL GFLNPRLYQQ HGAGLFDVTR GCHESCLDEE VEGQGFCSGP
     GWDPVTGWGT PNFPALLKTL LNP
//
